PD 166114

Drug Profile

PD 166114

Latest Information Update: 05 Oct 2001

Price : $50

At a glance

  • Originator Pfizer
  • Class Anti-ischaemics; Antihypertensives; Heart failure therapies; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cerebral ischaemia; Cerebral vasospasm; Heart failure; Hypertension; Renal failure

Most Recent Events

  • 05 Oct 2001 No-Development-Reported for Congestive heart failure in USA (Unknown route)
  • 05 Oct 2001 No-Development-Reported for Cerebral vasospasm in USA (Unknown route)
  • 05 Oct 2001 No-Development-Reported for Renal failure in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top